Article
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.
Cancer cell - 16 Jun 2014
Woll Petter S, Kjällquist Una, Chowdhury Onima, Doolittle Helen, Wedge David C, Thongjuea Supat, Erlandsson Rikard, Ngara Mtakai, Anderson Kristina, Deng Qiaolin, Mead Adam J, Stenson Laura, Giustacchini Alice, Duarte Sara, Giannoulatou Eleni, Taylor Stephen, Karimi Mohsen, Scharenberg Christian, Mortera-Blanco Teresa, Macaulay Iain C, Clark Sally-Ann, Dybedal Ingunn, Josefsen Dag, Fenaux Pierre, Hokland Peter, Holm Mette S, Cazzola Mario, Malcovati Luca, Tauro Sudhir, Bowen David, Boultwood Jacqueline, Pellagatti Andrea, Pimanda John E, Unnikrishnan Ashwin, Vyas Paresh, Göhring Gudrun, Schlegelberger Brigitte, Tobiasson Magnus, Kvalheim Gunnar, Constantinescu Stefan N, Nerlov Claus, Nilsson Lars, Campbell Peter J, Sandberg Rickard, Papaemmanuil Elli, Hellström-Lindberg Eva, Linnarsson Sten, Jacobsen Sten Eirik W
Abstract excerpt
Evidence for distinct human cancer stem cells (CSCs) remains contentious and the degree to which different cancer cells contribute to propagating malignancies in patients remains unexplored. In low- to intermediate-risk myelodysplastic syndromes (MDS), we establish the existence of rare multipotent MDS stem cells (MDS-SCs), and their hierarchical relationship to lineage-restricted MDS progenitors. All identified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.